The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

This difference from GLP-1 drug pharmacology ... dose study evaluating the safety, tolerability, and preliminary efficacy of RJVA-001 in adults with inadequately controlled T2D despite use of ...

Researchers at Clalit Health Services in Tel Aviv, Israel, conducted an observational study ... (GLP-1 RAs) — injectable medications for obesity and type 2 diabetes — with at least six drug ...

Higher body appreciation was highlighted as a protective factor against GLP-1 use. However, it is important to note that the study's cross-sectional design means these findings are correlational ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

This retrospective study suggests there is a cardioprotective effect of GLP-1RA compared ... antiarrhythmic drug use, cardioversion, or repeat ablation by 1 year. Similarly, in PULSED AF, around ...

including one study that showed improvement in sperm counts among men who lost weight initially by dietary intervention and then maintained the weight loss with exercise or use of GLP-1 agonists.